PMA supplement
P790017 S052: USCI(R)GRUNTZIG DILACA CATHETER
FDA PMA supplement · Normal 180 Day Track · Medtronic, Ireland
Key facts
| Original PMA | P790017 |
|---|---|
| Supplement number | S052 |
| Supplement type | Normal 180 Day Track |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | USCI(R)GRUNTZIG DILACA CATHETER |
| Generic name | Catheters, transluminal coronary angioplasty, percutaneous |
| Applicant | Medtronic, Ireland |
| Product code | LOX |
| Received date | Jun 23, 1993 |
| Decision date | Apr 18, 1996 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: